Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been named a Leader for the second consecutive time, in the IDC MarketScape for Worldwide Life Science R&D Strategic Consulting Services.1
According to the report, "TCS has extensive experience working with life science companies across all three sections of the industry: pharmaceutical, biotech, and medical devices." The report also noted, "Relative to other vendors discussed in this study and based on feedback from customer references, TCS received high marks for its technical skills, deep industry knowledge, competent end-to-end project delivery capabilities, and willingness to work as a partner to develop solution offerings on the cutting edge of life science innovation (e.g., TCS' Advanced Drug Development platform)."
"The life sciences industry continues to explore new growth avenues through technology-led innovations, proactive M&A pursuits, development of niche drugs, to enhance patient engagement and accelerate Business 4.0™ transformations," said Debashis Ghosh, President, Life Sciences and Healthcare, TCS. "This recognition by the /DC MarketScape is a validation of our vision, focus on innovation, and capabilities in consulting and advisory services."
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies. TCS offers a full set of services spanning advisory, digital transformation, and cognitive business operations in areas such as M&A and divestitures IT consulting, supply chain management, digitization of clinical trials, paperless and integrated lab environment, Blockchain-enabled clinical supply chain, AI enabled case processing, and discovery collaboration. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, Internet of Things and cloud to fully digitize life sciences value chain.
TCS' genomics and translational research offerings also deliver differentiated value to life sciences companies by combining bioinformatics analysis and DNA sequencing lab capabilities for emerging genomics-driven R&D initiatives.
Using TCS' Business 4.0™ thought leadership framework and deep contextual knowledge, its Life Sciences consultants help customers leverage digital technologies to gain a distinct edge in areas such as patient centricity, accelerated drug discovery, and clinical development.
"Strategic consulting in life sciences is more important than ever as industry transformation moves forward. Partnering with a strategic consulting service provider is a core strategy for success. TCS' Business 4.0™ thought leadership framework, technical and domain focus and ability to successfully partner with customers for development of cutting-edge life science innovations, makes it a preferred transformation partner to address strategic consulting needs," said Alan S. Louie, Research Director, IDC Health Insights Life Science R&D Strategies and Technology Research.
"Our Business 4.0™ vision, vast technical c;md domain knowledge, investments in future-ready solutions, and next generation platform solutions, position us as a preferred consulting partner for our customers in the life sciences industry," added Debashis Ghosh.
Shares of TATA CONSULTANCY SERVICES LTD. was last trading in BSE at Rs.2198.7 as compared to the previous close of Rs. 2103.8. The total number of shares traded during the day was 299610 in over 15149 trades.
The stock hit an intraday high of Rs. 2214.15 and intraday low of 2098.3. The net turnover during the day was Rs. 650156496.
1 IDC MarketScape: Worldwide Life Science R&D Strategic Consulting Services 2018 Vendor Assessment, Doc #US44159218, August 2018